Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of multi-armed pegized oritavancin derivative and its preparation

A technology of oritavancin and its derivatives, applied in the application field of multi-armed PEGylated oritavancin derivatives and their preparation, preparation and treatment of acute bacterial skin and skin structure infections, capable of solving To avoid problems such as limited quantity, to achieve the effects of convenient quality control, good drug activity in vivo and in vitro, and reduced toxic and side effects

Active Publication Date: 2022-05-06
湖南华腾医药有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ordinary straight-chain PEG has only two terminal modification groups. When connecting with small molecule drugs, the loading capacity is very limited, while multi-armed PEG has more than 2 modifiable terminals.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of multi-armed pegized oritavancin derivative and its preparation
  • A kind of multi-armed pegized oritavancin derivative and its preparation
  • A kind of multi-armed pegized oritavancin derivative and its preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] (1) Preparation of 4-Arm-PEG24-GA-II

[0029] Dissolve 10mmol of 4-Arm-PEG24-OH-I in 100ml of DMF, add 11mmol of adipic anhydride and 10mmol of DMAP at room temperature, and then stir at 100°C for 10h. After the reaction was completed, the solution was distilled off under reduced pressure to obtain a crude product. The crude product was purified by chromatography to obtain 4-Arm-PEG24-GA-II. Yield: 90%. NMR data are as follows: 1H NMR (400MHz, CDCl3) δ4.26(s,2H),3.66(m,96H),2.86(s,2H),2.74(s,2H),2.52(s,2H), 2.09( s,2H).

[0030] (2) Preparation of 4Arm-PEG24-oritavancin-II

[0031] Dissolve 10mmol of 4-Arm-PEGm-GA-II in 50ml of N,N-dimethylformamide, add 10mmol of DIC and 10mmol of 4-PPY, and stir at 25°C for 2h. 80 mmol of oritavancin was added to the reaction, and the reaction was carried out at 30°C for 12 hours. After the completion of the oritavancin reaction as detected by TLC tracking, 4Arm-PEG24-oritavancin-II was obtained by recrystallization and chromato...

Embodiment 2

[0033] (1) Preparation of 4-Arm-PEG124-GA-II

[0034] Dissolve 10mmol of 4-Arm-PEG124-OH-I in 100ml of DMF, add 11mmol of adipic anhydride and 10mmol of DMAP at room temperature, and then stir at 100°C for 8h. After the reaction was completed, the solution was distilled off under reduced pressure to obtain a crude product. The crude product was purified by chromatography to obtain (4or 6or 8)-Arm-PEGm-GA-II. Yield: 90%. NMR data are as follows: 1H NMR (400MHz, CDCl3) δ4.26(s,2H),3.66(m,496H),2.86(s,2H),2.74(s,2H),2.52(s,2H),2.09( s,2H).

[0035] (2) Preparation of 4Arm-PEG124-oritavancin-II

[0036] Dissolve 10mmol of 4-Arm-PEG24-GA-II in 50ml of N,N-dimethylformamide, add 10mmol of DIC and 10mmol of 4-PPY, and stir at 25°C for 2h. 80 mmol of oritavancin was added to the reaction, and the reaction was carried out at 30°C for 12 hours. After TLC tracking detection oritavancin reaction was complete, 4Arm-PEG124-oritavancin-II was obtained by recrystallization and chromatog...

Embodiment 3

[0038] (1) Preparation of 4-Arm-PEG240-GA-II

[0039] Dissolve 10mmol of 4-Arm-PEG240-OH-I in 100ml of DMF, add 11mmol of adipic anhydride and 10mmol of DMAP at room temperature, and then stir at 120°C for 10h. After the reaction was completed, the solution was distilled off under reduced pressure to obtain a crude product. The crude product was purified by chromatography to obtain 4-Arm-PEG240-GA-II. Yield: 90%. NMR data are as follows: 1H NMR (400MHz, CDCl3) δ4.26(s, 2H), 3.66(m, 960H), 2.86(s, 2H), 2.74(s, 2H), 2.52(s, 2H), 2.09( s,2H).

[0040] (2) Preparation of 4Arm-PEG240-oritavancin-II

[0041] Dissolve 10mmol of 4-Arm-PEG240-GA-II in 50ml of N,N-dimethylformamide, add 10mmol of DIC and 10mmol of 4-PPY, and stir at 25°C for 2h. 80 mmol of oritavancin was added to the reaction, and the reaction was carried out at 30°C for 12 hours. After TLC tracking detection oritavancin reaction was complete, 4Arm-PEG240-oritavancin-II was obtained by recrystallization and chromat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention utilizes the characteristics of non-toxicity and easy combination of multi-arm PEG to connect four-arm PEG, six-arm PEG and multi-arm PEG to oritavancin respectively. The multi-arm PEG-loaded oritavancin prodrug not only has good water solubility, the most important feature is that a multi-arm PEG chain can be connected to multiple oritavancin residues, the drug loading rate is greatly improved, and it The half-life of the drug is greatly extended, and its existence time in the plasma is significantly increased, thereby improving the curative effect.

Description

technical field [0001] The invention relates to the field of pharmaceutical synthesis, in particular to a multi-armed PEGylated oritavancin derivative and its preparation method and its application in the preparation and treatment of acute bacterial skin and skin structure infections. Background technique [0002] In recent years, with the increasing use of antibacterial drugs, the problem of bacterial resistance has become increasingly serious, and the proportion of MRSA in skin infections has increased year by year. Clinically, vancomycin and teicoplanin are usually used to treat serious infections caused by MRSA. However, the rapid emergence of vancomycin-resistant strains makes it urgent to find new anti-MRSA antibacterial drugs. [0003] Oritavancin is a second-generation glycopeptide antibacterial drug developed on the basis of vancomycin. It is the first and only single-agent antibacterial drug approved by the FDA for the treatment of ABSSSIs. The approval of oritav...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C08G65/337A61P31/02A61P31/04A61P17/00
CPCC08G65/337A61P31/02A61P31/04A61P17/00C08G2650/04
Inventor 张安林邓泽平成佳
Owner 湖南华腾医药有限公司